MD3976597T2 - Inhibitori cu molecula mică ai kinazei care induce NF-kB - Google Patents

Inhibitori cu molecula mică ai kinazei care induce NF-kB Download PDF

Info

Publication number
MD3976597T2
MD3976597T2 MDE20220374T MDE20220374T MD3976597T2 MD 3976597 T2 MD3976597 T2 MD 3976597T2 MD E20220374 T MDE20220374 T MD E20220374T MD E20220374 T MDE20220374 T MD E20220374T MD 3976597 T2 MD3976597 T2 MD 3976597T2
Authority
MD
Moldova
Prior art keywords
ethynyl
phenyl
pyrimidin
hydroxy
amino
Prior art date
Application number
MDE20220374T
Other languages
English (en)
Romanian (ro)
Inventor
J Kent Barbay
Wenying Chai
Wendy Eccles
Michael D Hack
Aaron T Herrmann
William M Jones
Paul J Krawczuk
Kevin D Kreutter
Alec D Lebsack
Daniel J Pippel
Alexander R Rovira
Ronald L Wolin
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MD3976597T2 publication Critical patent/MD3976597T2/ro

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/06Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MDE20220374T 2019-05-31 2020-05-29 Inhibitori cu molecula mică ai kinazei care induce NF-kB MD3976597T2 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855144P 2019-05-31 2019-05-31
US201962907833P 2019-09-30 2019-09-30
PCT/EP2020/065024 WO2020239999A1 (en) 2019-05-31 2020-05-29 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

Publications (1)

Publication Number Publication Date
MD3976597T2 true MD3976597T2 (ro) 2025-01-31

Family

ID=71108552

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20220374T MD3976597T2 (ro) 2019-05-31 2020-05-29 Inhibitori cu molecula mică ai kinazei care induce NF-kB

Country Status (37)

Country Link
US (3) US11254673B2 (https=)
EP (2) EP3976597B1 (https=)
JP (2) JP7547387B2 (https=)
KR (1) KR20220027871A (https=)
CN (2) CN114222737B (https=)
AU (1) AU2020282005B2 (https=)
BR (1) BR112021023796A2 (https=)
CL (1) CL2021003142A1 (https=)
CO (1) CO2021017838A2 (https=)
CR (1) CR20210587A (https=)
DK (1) DK3976597T3 (https=)
DO (1) DOP2021000244A (https=)
EC (1) ECSP21093623A (https=)
ES (1) ES2989387T3 (https=)
FI (1) FI3976597T3 (https=)
HR (1) HRP20241352T1 (https=)
HU (1) HUE068694T2 (https=)
IL (1) IL288387B2 (https=)
JO (1) JOP20210318B1 (https=)
LT (1) LT3976597T (https=)
MA (1) MA56038B1 (https=)
MD (1) MD3976597T2 (https=)
MX (1) MX2021014679A (https=)
MY (1) MY205653A (https=)
PE (1) PE20220768A1 (https=)
PH (1) PH12021553011A1 (https=)
PL (1) PL3976597T3 (https=)
PT (1) PT3976597T (https=)
RS (1) RS66105B1 (https=)
SA (1) SA521430960B1 (https=)
SG (1) SG11202112994WA (https=)
SI (1) SI3976597T1 (https=)
SM (1) SMT202400418T1 (https=)
TW (2) TWI850390B (https=)
UA (1) UA130430C2 (https=)
UY (1) UY38721A (https=)
WO (1) WO2020239999A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114222737B (zh) * 2019-05-31 2024-07-26 詹森药业有限公司 NF-κB诱导激酶的小分子抑制剂
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR20220030222A (ko) 2019-05-31 2022-03-10 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
IL316886A (en) * 2022-05-11 2025-01-01 Janssen Pharmaceutica Nv History of pyrrolidinones as NF kappa B kinase inhibitors
CA3257152A1 (en) * 2022-05-11 2023-11-16 Janssen Pharmaceutica Nv Pyrrolidine derivatives useful as NF-κB induction kinase inhibitors
EP4637773A1 (en) 2022-12-22 2025-10-29 Boehringer Ingelheim International GmbH Crystalline forms of a her2 inhibitor
WO2025020886A1 (zh) * 2023-07-27 2025-01-30 浙江星浩澎博医药有限公司 氮杂喹唑啉环衍生物及其用途
IL326016A (en) 2023-07-28 2026-03-01 Boehringer Ingelheim Int Process for manufacturing a HER2 inhibitor
WO2025235874A1 (en) * 2024-05-10 2025-11-13 Schrödinger, Inc. Heterocyclics as egfr inhibitors
JP2026022634A (ja) * 2024-07-30 2026-02-12 日本たばこ産業株式会社 ピラゾロピリミジン化合物及びその医薬用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7132428B2 (en) 2003-07-03 2006-11-07 Aventis Pharmaceuticals Inc. Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
JP2008509138A (ja) * 2004-08-03 2008-03-27 ワイス 心臓血管疾患の治療に有用なインダゾール類
WO2006053277A2 (en) 2004-11-12 2006-05-18 Chippac, Inc. Wire bond interconnection
AU2009263037B2 (en) * 2008-06-26 2011-10-06 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
MX2013010513A (es) * 2011-03-16 2013-10-07 Hoffmann La Roche Compuestos de alcohol 6,5-heterociclil-propargilico y usos de los mismos.
JP2015507001A (ja) 2012-02-17 2015-03-05 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 三環式化合物及びその使用方法
US8859553B2 (en) * 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
US20150057260A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Alkynyl alcohols and methods of use
US20160096850A9 (en) * 2013-08-22 2016-04-07 Genentech, Inc. Alkynyl alcohols and methods of use
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作NIK抑制劑之新的1-(4-嘧啶基)-1H-吡唑並[3,2-c]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為NIK抑制劑的新穎3-(1H-吡唑-4-基)-1H-吡咯并[2,3-c]吡啶衍生物
AU2015334917B2 (en) 2014-10-23 2019-08-29 Janssen Pharmaceutica Nv New compounds as NIK inhibitors
BR112017008039B1 (pt) 2014-10-23 2023-04-11 Janssen Pharmaceutica N.V. Derivados de pirazol como inibidores de nik, seu uso no tratamento ou prevenção de câncer e composição farmacêutica que os compreende
JP6616412B2 (ja) 2014-10-23 2019-12-04 ヤンセン ファーマシューティカ エヌ.ベー. Nik阻害剤としての新規のピラゾロピリミジン誘導体
MX371151B (es) 2014-10-23 2020-01-20 Janssen Pharmaceutica Nv NUEVOS DERIVADOS DE TIENOPIRIMIDINA EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
JP2018510140A (ja) 2015-02-25 2018-04-12 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft アルキニルアルコール及び使用方法
ES2775449T3 (es) 2016-01-22 2020-07-27 Janssen Pharmaceutica Nv Nuevos derivados de cianoindolina sustituida como inhibidores de nik
EP3405464B1 (en) 2016-01-22 2019-12-04 Janssen Pharmaceutica NV New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
ES2837157T3 (es) 2016-06-30 2021-06-29 Janssen Pharmaceutica Nv Derivados de cianoindolina como inhibidores de NIK
WO2018002217A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Heteroaromatic derivatives as nik inhibitors
WO2018037058A1 (en) * 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
WO2018037059A1 (en) 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
CN110831940B (zh) 2017-07-06 2023-06-20 詹森药业有限公司 作为nik抑制剂的新取代的氮杂吲哚啉衍生物
CN109810110B (zh) * 2017-11-22 2023-01-24 中国科学院上海药物研究所 一种具有2-氨基嘧啶结构的化合物,其制备方法和用途
CN114222737B (zh) * 2019-05-31 2024-07-26 詹森药业有限公司 NF-κB诱导激酶的小分子抑制剂
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
KR20220030222A (ko) 2019-05-31 2022-03-10 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
BR112021022099A2 (pt) 2019-05-31 2021-12-28 Chiesi Farm Spa Derivados de amino quinazolina como inibidores de p2x3
WO2021067217A1 (en) 2019-09-30 2021-04-08 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators

Also Published As

Publication number Publication date
US20230080834A1 (en) 2023-03-16
WO2020239999A1 (en) 2020-12-03
ES2989387T3 (es) 2024-11-26
EP4467199A3 (en) 2025-03-05
US20210300918A1 (en) 2021-09-30
SMT202400418T1 (it) 2024-11-15
IL288387B1 (en) 2025-09-01
UY38721A (es) 2020-11-30
FI3976597T3 (fi) 2024-09-25
BR112021023796A2 (pt) 2022-02-08
TW202110842A (zh) 2021-03-16
MY205653A (en) 2024-11-02
KR20220027871A (ko) 2022-03-08
LT3976597T (lt) 2024-10-10
PE20220768A1 (es) 2022-05-16
US20240199605A1 (en) 2024-06-20
RS66105B1 (sr) 2024-11-29
JP7547387B2 (ja) 2024-09-09
JP2024167319A (ja) 2024-12-03
SG11202112994WA (en) 2021-12-30
IL288387A (en) 2022-01-01
TWI906955B (zh) 2025-12-01
MA56038B1 (fr) 2024-11-29
TW202517638A (zh) 2025-05-01
EP3976597B1 (en) 2024-08-28
CN118908957A (zh) 2024-11-08
TWI850390B (zh) 2024-08-01
UA130430C2 (uk) 2026-02-18
SI3976597T1 (sl) 2024-11-29
JOP20210318B1 (ar) 2025-10-01
EP3976597A1 (en) 2022-04-06
HRP20241352T1 (hr) 2024-12-20
CR20210587A (es) 2022-02-11
US11827634B2 (en) 2023-11-28
SA521430960B1 (ar) 2024-11-12
PH12021553011A1 (en) 2022-11-07
DK3976597T3 (da) 2024-09-09
ECSP21093623A (es) 2022-01-31
PT3976597T (pt) 2024-10-22
HUE068694T2 (hu) 2025-01-28
MA56038A (fr) 2022-04-06
AU2020282005A1 (en) 2021-12-23
CN114222737A (zh) 2022-03-22
PL3976597T3 (pl) 2024-12-16
JOP20210318A1 (ar) 2023-01-30
CN114222737B (zh) 2024-07-26
CO2021017838A2 (es) 2022-01-17
CL2021003142A1 (es) 2022-08-19
IL288387B2 (en) 2026-01-01
AU2020282005B2 (en) 2026-02-12
MX2021014679A (es) 2022-04-06
CA3143350A1 (en) 2020-12-03
US11254673B2 (en) 2022-02-22
JP2022534302A (ja) 2022-07-28
EP4467199A2 (en) 2024-11-27
DOP2021000244A (es) 2022-04-18

Similar Documents

Publication Publication Date Title
US11827634B2 (en) Small molecule inhibitors of NF-kB inducing kinase
EP4067347B1 (en) Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer
CN114945366A (zh) Hpk1拮抗剂和其用途
JP2021001212A (ja) Btk阻害薬としての一級カルボキサミド類
JP2024509192A (ja) Hpk1アンタゴニスト及びその使用
JP2023516551A (ja) 大環状rip2-キナーゼ阻害剤
WO2020223590A1 (en) Modulators of trex1
CA3143350C (en) Small molecule inhibitors of nf-kb inducing kinase
US20230416256A1 (en) SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE
HK40119602A (en) Small molecule inhibitors of nf-kb inducing kinase
HK40071178A (en) Small molecule inhibitors of nf-kb inducing kinase
HK40071178B (en) Small molecule inhibitors of nf-kb inducing kinase
EA045720B1 (ru) НИЗКОМОЛЕКУЛЯРНЫЕ ИНГИБИТОРЫ NF-κB-ИНДУЦИРУЮЩЕЙ КИНАЗЫ
WO2026064602A1 (en) HETEROCYCLIC COMPOUNDS AS MODULATORS OF TNFα ACTIVITY
US20250282785A1 (en) Pyrrolidinone derivatives as inhibitors of nf kappa b inducing kinase